Imperfect rationality, macroeconomic equilibrium and price rigidities

We introduce some elements of Prospect Theory into a general equilibrium model with monoolistic competition in the good market and real wage rigidities due to (right to manage or efficient) wage bargaining, or to efficiency wages. We show that, under these types of labor market frictions, an increase in workers’ loss aversion: (i) reduces the equilibrium wage and in this way increases potential output; (ii) induces workers to work and consume less and in this way decreases potential output. If the former effect is greater (smaller) than the latter one, loss aversion increases (decreases) potential output. We also show that, under all the types of labor market frictions we consider, if loss aversion reduces equilibrium output, it also enhances the plausibility of nominal price rigidities

LHC sensitivity to Z'/W' states in composite Higgs models

Using the 4-Dimensional Composite Higgs Model (4DCHM) realization of the minimal composite Higgs scenario, we discuss the Large Hadron Collider (LHC) sensitivity to new physics signals from multiple $Z^\prime$ and $W^\prime$ broad resonances. We illustrate the role of systematic uncertainties due to QCD effects encoded in parton distribution functions for experimental searches in leptonic channels. We show that, by reducing this systematics through the combination of high-precision measurements of Standard Model (SM) lepton-charge and forward-backward asymmetries near the SM vector-boson peak, the sensitivity to the new physics signals can be greatly enhanced.Comment: 6 pages, 1 figure, Contribution to ICHEP2022 Conference Proceedings based on arXiv:2111.09698, arXiv:2206.1246

Effect of a cognitive training program on the platelet app ratio in patients with alzheimer’s disease

In patients with Alzheimer’s disease (AD), synaptic plasticity seems to be involved in cognitive improvement induced by cognitive training. The platelet amyloid precursor protein (APP) ratio (APPr), i.e., the ratio between two APP isoforms, may be a useful peripheral biomarker to investigate synaptic plasticity pathways. This study evaluates the changes in neuropsychological/cognitive performance and APPr induced by cognitive training in AD patients participating in the “My Mind Project”. Neuropsychological/cognitive variables and APPr were evaluated in the trained group (n = 28) before a two-month experimental protocol, immediately after its termination at follow-up 1 (FU1), after 6 months at follow-up 2 (FU2), and after 24 months at follow-up 3 (FU3). The control group (n = 31) received general psychoeducational training for two months. Some memory and attention parameters were significantly improved in trained vs. control patients at FU1 and FU2 compared to baseline (∆ values). At FU3, APPr and Mini Mental State Examination (MMSE) scores decreased in trained patients. ∆ APPr correlated significantly with the ∆ scores of (i) MMSE at FU1, (ii) the prose memory test at FU2, and (iii) Instrumental Activities of Daily Living (IADL), the semantic word fluency test, Clinical Dementia Rating (CDR), and the attentive matrices test at FU3. Our data demonstrate that the platelet APPr correlates with key clinical variables, thereby proving that it may be a reliable biomarker of brain function in AD patients

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety

Abiraterone acetate (AA) is a potent, selective androge (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the safety and efficacy of AA in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units, after the approval of the drug from the Italian Drug Agency (AIFA)

Report on the activity of the GILDA-CRG beamline 2009-2013

Index Technical description of the beamline..................................................................................................3 Introduction ....................................................................................................................................3 Optics..............................................................................................................................................3 The XAS end station........................................................................................................................6 Standard data collection setup.....................................................................................................6 Surface XAS apparata.................................................................................................................8 Recent sample environment and Instrumentation developments................................................9 The x-ray diffraction (XRD) end-station.......................................................................................13 Beamline control...........................................................................................................................14 Administrative aspects........................................................................................................................16 Organisation..................................................................................................................................16 Beamline Staff Situation................................................................................................................17 Statistical data on Users and scientific production.............................................................................21 Future perspectives and plans for upgrade.........................................................................................25 Aim of the project.........................................................................................................................25 Design...........................................................................................................................................26 Timetable......................................................................................................................................31 Overview of the overall scientific activity.........................................................................................33 Selection of five publications........................................................................................................33 Highlights of the scientific activity................................................................................................34 Local order in semiconductors..................................................................................................34 Nanotechnology.......................................................................................................................44 Cements and porous systems....................................................................................................48 Chemistry.................................................................................................................................56 Earth Science............................................................................................................................61 Environment.............................................................................................................................67 Cultural Heritage.......................................................................................................................72 Health, medicine and life science .............................................................................................77 Acknowledgements...........................................................................................................................84 References.........................................................................................................................................85 Generic References.......................................................................................................................85 GILDA 2009-2013 Publications....................................................................................................8

Current trends in ATRA delivery for cancer therapy

All-Trans Retinoic Acid (ATRA) is the most active metabolite of vitamin A. It is critically involved in the regulation of multiple processes, such as cell differentiation and apoptosis, by activating specific genomic pathways or by influencing key signaling proteins. Furthermore, mounting evidence highlights the anti-tumor activity of this compound. Notably, oral administration of ATRA is the first choice treatment in Acute Promyelocytic Leukemia (APL) in adults and NeuroBlastoma (NB) in children. Regrettably, the promising results obtained for these diseases have not been translated yet into the clinics for solid tumors. This is mainly due to ATRA-resistance developed by cancer cells and to ineffective delivery and targeting. This up-to-date review deals with recent studies on different ATRA-loaded Drug Delivery Systems (DDSs) development and application on several tumor models. Moreover, patents, pre-clinical, and clinical studies are also reviewed. To sum up, the main aim of this in-depth review is to provide a detailed overview of the several attempts which have been made in the recent years to ameliorate ATRA delivery and targeting in cancer

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective analysis of progression-free (PFS) and overall survival (OS) in the “Real Life”

Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the PFS and OS safety in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units

Removal of enteric viruses and Escherichia coli from municipal treated effluent by zebra mussels

Dreissena polymorpha is a widespread filter-feeder species, resistant to a broad range of environmental conditions and different types of pollutants, which has recently colonized Italian freshwaters. Although widely used to monitor pollution in freshwater environments, this species is also an important food source for some fish and water birds. It can also be used to concentrate or remove particulate organic matter to interrupt avian-to-human transmission of pollutants and control health risks for animals and humans. In this study, the accumulation/inactivation in D. polymorpha of human health-related spiked enteric viruses was described. The removal of endogenous Escherichia coli, the classical indicator of fecal contamination, was tested as well. Our preliminary lab-scale results demonstrate that zebra mussels can reduce significantly poliovirus titer after 24 h and rotavirus titer after 8 h. E. coli counts were also reduced in the presence of zebra mussels by about 1.5 log after 4 h and nearly completely after 24 h. The fate of the two enteric viruses after concentration by zebra mussels was also investigated after mechanical disruption of the tissues. To our knowledge, the accumulation from water and inactivation of human health-related enteric viruses by zebra mussels has never been reported